Idiopathic Pulmonary Fibrosis

ClinicalAugust 11, 2026

Buloxibutid trial initiated for idiopathic pulmonary fibrosis with efficacy and safety evaluation

The ASPIRE trial has been initiated to evaluate the efficacy, safety, and pharmacokinetics of buloxibutid in patients with idiopathic pulmonary fibrosis (IPF).

Companies

Assets

Recent signals(8)

Study on Plasma Exchange and Rituximab for Severe Acute Exacerbation of IPF

Buloxibutid trial initiated for idiopathic pulmonary fibrosis with efficacy and safety evaluation

Phase 2 Study of PIPE-791 in Idiopathic Pulmonary Fibrosis Initiated by Contineum Therapeutics

Phase 2 Study of LTI-03 in Idiopathic Pulmonary Fibrosis Patients Initiated by Rein Therapeutics

Nerandomilast (Jascayd) Approved for Idiopathic and Progressive Pulmonary Fibrosis

Aurobindo Pharma's Pirfenidone ANDA Submission Receives AP Status

Phase IIb Trial of Autoantibody Reduction Therapy for Progressive IPF Initiated

Phase 2 Trial of Nintedanib DPI in Idiopathic Pulmonary Fibrosis Initiated by Mannkind Corporation

Upcoming catalysts

Indications

Get signals before the market moves